

Nuclear Hormone Retinoid X Receptor (RXR) Negatively Regulates the Glucose-Stimulated Insulin Secretion of Pancreatic β -Cells

Satsuki Miyazaki,¹ Hidenori Taniguchi,¹ Yusuke Moritoh,¹ Fumi Tashiro,¹ Tsunehiko Yamamoto,¹ Eiji Yamato,¹ Hiroshi Ikegami,² Keiko Ozato,³ and Jun-ichi Miyazaki¹

OBJECTIVE—Retinoid X receptors (RXRs) are members of the nuclear hormone receptor superfamily and are thought to be key regulators in differentiation, cellular growth, and gene expression. Although several experiments using pancreatic β -cell lines have shown that the ligands of nuclear hormone receptors modulate insulin secretion, it is not clear whether RXRs have any role in insulin secretion.

RESEARCH DESIGN AND METHODS—To elucidate the function of RXRs in pancreatic β -cells, we generated a double-transgenic mouse in which a dominant-negative form of RXR β was inducibly expressed in pancreatic β -cells using the Tet-On system. We also established a pancreatic β -cell line from an insulinoma caused by the β -cell-specific expression of simian virus 40 T antigen in the above transgenic mouse.

RESULTS—In the transgenic mouse, expression of the dominant-negative RXR enhanced the insulin secretion with high glucose stimulation. In the pancreatic β -cell line, the suppression of RXRs also enhanced glucose-stimulated insulin secretion at a high glucose concentration, while 9-*cis*-retinoic acid, an RXR agonist, repressed it. High-density oligonucleotide microarray analysis showed that expression of the dominant-negative RXR affected the expression levels of a number of genes, some of which have been implicated in the function and/or differentiation of β -cells.

CONCLUSIONS—These results suggest that endogenous RXR negatively regulates the glucose-stimulated insulin secretion. Given these findings, we propose that the modulation of endogenous RXR in β -cells may be a new therapeutic approach for improving impaired insulin secretion in type 2 diabetes. *Diabetes* 59:2854–2861, 2010

From the ¹Division of Stem Cell Regulation Research, Osaka University Graduate School of Medicine, Osaka, Japan; the ²Department of Endocrinology, Metabolism and Diabetes, Kinki University School of Medicine, Osaka, Japan; and the ³Section on Molecular Genetics of Immunity, Laboratory of Molecular Growth Regulation, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.

Corresponding author: Jun-ichi Miyazaki, jimiya@nutri.med.osaka-u.ac.jp. Received 28 December 2009 and accepted 13 August 2010. Published ahead of print at <http://diabetes.diabetesjournals.org> on 26 August 2010. DOI: 10.2337/db09-1897.

S.M. and H.T. contributed equally to this work.

© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nuclear hormone receptor superfamily plays essential roles in various aspects of biological regulation, such as differentiation, cellular growth, and metabolism. The retinoid X receptors (RXRs) play a unique and central role in the activity of many members of this superfamily. They function as an obligate heterodimeric partner for retinoic acid receptors (RARs), thyroid hormone receptor, vitamin D receptor, peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), farnesoid X receptor, and others (1). Because of this unique position within the superfamily, the modulation of the activity of RXRs is considered to cause a broad spectrum of effects (2,3).

In pancreatic β -cells, there are several lines of evidence from in vitro studies that nuclear receptors are involved in the insulin secretory mechanism. Retinoic acid affects the expression of the glucokinase and preproinsulin genes and promotes insulin secretion in RIN-m5F cells (4,5) and in isolated islets (6). In INS-1 cells, both 9-*cis*-retinoic acid (9cRA), a ligand of RXRs, and all-*trans*-retinoic acid (ATRA), a ligand of RARs, increase insulin secretion, and ATRA raises GLUT2 mRNA (7). In contrast, 9cRA and a high concentration of rosiglitazone, a ligand of PPAR- γ , are reported to inhibit glucose-stimulated insulin secretion (GSIS) in INS-1 cells (7), suggesting that the PPAR/RXR heterodimer is inhibitory to insulin secretion in β -cells. Recent reports showed that the co-overexpression of PPAR- α and RXR- α in INS-1 cells potentiated glucose-induced insulin secretion, whereas the co-overexpression of PPAR- γ and RXR- α in INS-1 cells attenuated it (8). Although these results suggest that RXR plays a role in regulating the insulin secretory machinery of β -cells, it is still controversial whether RXR has a direct effect on insulin secretion.

RXR is composed of three family members—RXR- α , - β , and - γ —that have redundant roles (8–10). Therefore, it is necessary to disrupt the genes for all three RXR members to inactivate RXR function. Considering the practical difficulty of a β -cell-specific knockout of all three genes, we took another approach using a dominant-negative form of RXR. RXR $\beta\Delta C2$, which lacks the ligand-binding domain, is known to act as a dominant-negative receptor and to inhibit the ligand-dependent transcriptional activation of target genes by homodimerized and heterodimerized RXRs (11). To investigate the in vivo function of RXR in β -cells, we generated a double-transgenic (Tg) mouse: one transgene expresses reverse tetracycline-regulated transactivator (rtTA) under the insulin promoter, and the other expresses RXR $\beta\Delta C2$ under the tetracycline-responsive TetO promoter. In this Tg mouse line, the addition of




FIG. 1. DNA constructs used to generate transgenic mice. Two transgenes were constructed to enable the Tet-On system to work: the transgene termed *Ins-rtTA* (A) carried the reverse tetracycline-regulated transactivator (*rtTA*) gene under the human insulin promoter, and the other transgene, termed *TetO-RXR β Δ C2* (B), carried the *RXR β Δ C2* cDNA, which encodes a dominant-negative form of mouse *RXR β* lacking 20 conserved COOH-terminal amino residues of the ligand-binding and dimerization domain, following the TetO promoter. DBD, DNA-binding domain; LBD, ligand-binding domain. (A high-quality color representation of this figure is available in the online issue.)

tetracycline to the drinking water led to the expression of *RXR β Δ C2* in the β -cells. The tetracycline-treated Tg mice showed elevated glucose tolerance, and islets isolated from these mice also showed enhanced GSIS.

To examine the role of *RXR* in β -cells, we established β -cell lines (*dnRXR-MIN6* cells) from an insulinoma that developed in a triple-Tg mouse harboring the SV40 T antigen gene under the insulin promoter in addition to the two transgenes for *RXR β Δ C2* expression. Using this cell line, we confirmed that the suppression of *RXR* enhanced the glucose-stimulated insulin secretion at a high glucose concentration *in vitro*. High-density oligonucleotide microarray analysis showed that the expression of a number of genes was affected by the suppression of *RXR*. Our findings suggest that modulating the activity of the endogenous *RXRs* in β -cells may provide a novel therapeutic approach for improving impaired insulin secretion in type 2 diabetes.

RESEARCH DESIGN AND METHODS

Generation of double-Tg mice. To generate Tg mice in which the expression of a dominant-negative form of *RXR β* could be induced in β -cells, we designed two transgenes to use the Tet-On system (12–14). The first transgene, *Ins-rtTA*, carried the reverse tetracycline-regulated transactivator (*rtTA*) gene under the human insulin promoter (Fig. 1A). The second transgene, *TetO-RXR β Δ C2*, carried the *RXR β Δ C2* cDNA, which encodes a dominant-negative form of mouse *RXR β* , lacking 20 conserved COOH-terminal amino residues of the ligand-binding and dimerization domain (11), and the human growth hormone gene, including the polyadenylation signal, following the TetO promoter (Fig. 1B). Tg mice were generated by DNA microinjection into the pronuclei of fertilized eggs of C57BL/6J. Tg founder mice were identified by PCR analyses of the genomic DNA obtained from tail tips. In the *Ins-rtTA/TetO-RXR β Δ C2* double-Tg mice, the islet-specific expression of *rtTA* and inducible expression of *RXR β Δ C2* were confirmed by RT-PCR and immunohistochemical analyses. For doxycycline (Dox) treatment, doxycycline hydrochloride (Sigma-Aldrich, St. Louis, MO) was dissolved in water at a concentration of 1 mg/ml, and this solution was used as the drinking water for the double-Tg mice.

Oral glucose tolerance test. An oral glucose tolerance test (OGTT) was performed twice on the same groups of the double-Tg mice: after 2 weeks of Dox treatment (Dox On) and 2 weeks after the withdrawal of Dox treatment (Dox Off). The Tg mice were fasted overnight for 16 h followed by oral administration of glucose (2 g/kg body wt). Blood samples were collected by retro-orbital sinus puncture before (0 min) and 10, 30, 60, and 120 min after

glucose administration. Plasma samples were obtained by centrifugation at 4°C and were stored at –80°C until analysis. The plasma glucose and insulin concentrations were measured using a blood glucose test kit (Glucose CII-test; Wako Pure Chemicals, Osaka, Japan) and an enzyme-linked immunosorbent assay (ELISA) kit (Morinaga, Yokohama, Japan), respectively.

Measurement of insulin secretion and insulin content. Double-Tg mice with or without 2 weeks of Dox treatment were killed, and their islets were isolated according to a previously described method (15). The isolated islets were cultured in RPMI medium with 11 mmol/l glucose, 10% FBS, and antibiotics. For the islets from Dox-treated Tg mice, 5 μ g/ml Dox was added to the medium. After cultivation for 24 h, 10 μ mol/l 9cRA was added to the culture of half of the islets from Dox-treated Tg mice and that from Dox-untreated Tg mice. After further cultivation for 20 h, the islets of a similar size were washed with Krebs-Ringer bicarbonate buffer (KRBB) containing 0.2% BSA and transferred to microcentrifuge tubes (10 islets per tube; $n = 5$ –6 for each group). They were then cultured in KRBB containing 0.2% BSA with 3, 9, or 27 mmol/l glucose for 60 min, and the supernatant was collected and assayed for insulin using an ELISA kit (Mercodia, Uppsala, Sweden). For measurement of insulin content, double-Tg mice with or without 2 weeks of Dox treatment were killed and their pancreases were isolated. Insulin was extracted from them with acid ethanol and measured by immunoassay as described above.

Establishment of the *dnRXR-MIN6* β -cell lines. To establish β -cell lines with inducible *RXR β Δ C2* expression, *Ins-rtTA/TetO-RXR β Δ C2* double-Tg mice were mated with IT-6 Tg mice. IT-6 Tg mice bear the SV40 T antigen gene under the human insulin promoter and were originally used to establish MIN6 cells, a β -cell line that retains GSIS (16). The resulting triple-Tg mice were identified by the PCR analysis of genomic DNA obtained from the tail tips. Pancreatic β -cell lines were generated from 22 insulinomas isolated from the triple-Tg mice at the age of 9 weeks. Finally, two clones with good GSIS and stable induction of *RXR β Δ C2* by Dox were selected (named *dnRXR-MIN6*) and used for experiments.

Western blotting and immunocytochemistry. The total protein was extracted from *dnRXR-MIN6* cells after cultivation with or without Dox for 4 days and subjected to Western blotting using a mouse anti-mouse *RXR β* monoclonal antibody (MA3-812 [clone MOK13.17]; Affinity Bioreagents, Golden, CO) that detects *RXR β Δ C2* (11) and a horseradish peroxidase-conjugated second antibody. Detection was done by enhanced chemiluminescence (ECL kit; Amersham, Arlington Heights, IL). Immunocytochemistry was performed with *dnRXR-MIN6* cells. The cultured cells were washed with PBS and fixed in 4% paraformaldehyde for 10 min. After fixation, the cells were rinsed with PBS, incubated for 5 min in 1% Triton X-100, and, after a second wash, incubated in a blocking reagent. The samples were incubated with the first antibody for 60 min at room temperature, washed with PBS, and then incubated with the second antibody for 60 min at room temperature. The primary antibody was a mouse anti-mouse *RXR β* antibody (MOK13.17); the secondary antibody was Alexa Fluor 488-conjugated anti-mouse IgG₁ (Molecular Probes, Eugene, OR).

Immunohistochemical analyses. Immunohistochemistry was performed with frozen sections or paraffin sections of pancreatic tissue. The 8- μ m-thick frozen sections were placed on slides and fixed in cold acetone for 10 min. Pancreatic tissue was also fixed in 4% paraformaldehyde overnight and processed for paraffin embedding. Sections of paraffin-embedded pancreatic tissue (3–5 μ m thick) were deparaffinized and dehydrated. The frozen and paraffin sections were incubated with 3% normal goat serum in PBS containing 10% Blocking One (Nacalai Tesque, Kyoto, Japan) for 60 min at room temperature. The sections were then incubated with the first antibody at 4°C overnight and with a fluorescein-conjugated second antibody for 60 min at room temperature. After each antibody incubation, the sections were washed in PBS for 5 min with three changes. The first antibodies were guinea pig anti-insulin antibody (Dako, Carpinteria, CA), rabbit anti-VP16 antibody for the detection of *rtTA*, and mouse anti-mouse *RXR β* antibody. The secondary antibodies were Alexa Fluor 594-conjugated anti-guinea pig IgG, Alexa Fluor 488-conjugated anti-rabbit IgG, and Alexa Fluor 488-conjugated anti-mouse IgG₁ (Molecular Probes). The sections were observed by fluorescence microscopy (Olympus, Tokyo, Japan).

RT-PCR and real-time PCR analyses. The total RNA was extracted from isolated islets and *dnRXR-MIN6* cells after they were cultivated with or without Dox for 4 days by the acid guanidinium-phenol-chloroform method and was subjected to cDNA synthesis using ReverTra Ace α (Toyobo, Tokyo, Japan) (17). The cDNA was subjected to PCR with the following primers: *rtTA* forward primer, 5'-CGCATTAGAGCTGCTTAAT-3' and backward primer, 5'-TGACTTAGTAAAGCACATCT-3'; *RXR* forward primer, 5'-GCTGCTGTTACGTCTTCCTG-3' and backward primer 5'-AGCGTTGTCAAAAAGCCTGG-3' that binds to the sequence within the second exon of the human growth hormone gene in the *TetO-RXR β Δ C2* transgene; and *HPRT* forward primer, 5'-CTCGAAGTGTG GATACAGG-3' and backward primer, 5'-TGGCCTATAGGCTCATAGTG-3'. These

primers were designed to encompass intronic sequences to distinguish the appropriate PCR products from products amplified from contaminating genomic DNA. Real-time PCR was performed on an ABI Prism 7300 Sequence Detection System (Applied Biosystems, Foster City, CA), using the SYBR Green PCR core reagents detection system (Applied Biosystems). The primer sequences are shown in supplementary Table 1. PCR was performed with an initial step of 10 s at 95°C followed by 40 cycles of 5 s at 95°C and 31 s at 60°C. The levels of targeted gene expression were normalized to that of β -actin. Statistical analysis was performed by a Student *t* test.

Glucose-stimulated insulin secretion in vitro. dnRXR-MIN6 cells were cultured in 24-well plates with Dulbecco's modified Eagle's medium in the presence or absence of 2 μ g/ml Dox for 4 days. In some experiments, 5 μ mol/l 9cRA was added for the last 2 days of culture. Cells were starved in KRBB containing 0.1% BSA and 3 mmol/l glucose for 1 h, and wells were replenished with the same buffer twice. Then, cells were stimulated with 3, 10, or 25 mmol/l glucose in 500 μ l KRBB containing 0.1% BSA for 1 h. The supernatants were collected and assayed for insulin using an ELISA kit. The values were normalized to the protein amount of each well. Statistical analysis was performed by a Student *t* test.

Microarray analysis. Total RNA was extracted by the acid guanidinium-phenol-chloroform method from dnRXR-MIN6 cells, after they were cultivated with or without Dox for 4 days. The quality of the purified total RNA was examined with an Agilent 2100 Bioanalyzer. We used 500 ng verified RNA to obtain cyanine 3 (Cy3)- or cyanine 5 (Cy5)-labeled cRNA using a Low RNA Input Fluorescent Linear Amplification Kit (Agilent), following the protocols recommended by the manufacturer. The cRNA was purified with RNeasy mini spin columns (Qiagen), and then 0.75 μ g each of the Cy3- and Cy5-labeled cRNAs were combined, fragmented, and used for hybridization to a high-density oligonucleotide microarray (Affymetrix). For the first hybridization, we used RNA from dnRXR-MIN6 Dox(+) (Cy3) and dnRXR-MIN6 Dox(-) (Cy5), and for the second, we used RNA from dnRXR-MIN6 Dox(+) (Cy3) and dnRXR-MIN6 Dox(-) (Cy5). We quantified the image using Agilent Feature Extraction Software.

RESULTS

Islet-specific overexpression of RXR β Δ C2 in Ins-rtTA/TetO-RXR β Δ C2 double-Tg mice. To achieve tetracycline-inducible expression of the RXR β Δ C2 gene in vivo, two types of Tg mouse were generated. The first Tg mouse, Ins-rtTA, expressed rtTA under the human insulin promoter (Fig. 1A). One line was obtained, and the specific expression of rtTA in the pancreas of these mice was confirmed by RT-PCR analysis (Fig. 2A). Immunohistochemical staining of the pancreas using an anti-VP16 antibody for the detection of rtTA confirmed the islet-specific expression of rtTA, while the pancreas of non-Tg control mice did not show specific staining (Fig. 2B). The second Tg mouse was termed TetO-RXR β Δ C2 (Fig. 1B). To select one line out of the five obtained, an adenoviral vector AdV-rtTA, which expressed the rtTA gene under the control of the ubiquitous promoter (18), was injected into one mouse of each TetO-RXR β Δ C2 Tg line via the tail vein. After 1 week of Dox treatment, the isolated livers were subjected to Western blotting analysis with an anti-RXR β antibody. One line in which RXR β Δ C2 was properly induced in the liver was selected. Finally, the Ins-rtTA/TetO-RXR β Δ C2 double-Tg mice were generated as described in RESEARCH DESIGN AND METHODS. These mice are called dominant-negative RXR (dnRXR) Tg mice in the following study.

RT-PCR analysis showed that RXR β Δ C2 was expressed only in the islets of the Dox-treated double-Tg mice (Fig. 2C). Immunohistochemical analysis showed that the nuclei of the islet β -cells of Dox-treated dnRXR Tg mice [Dox(+)] were more strongly stained with an anti-RXR β antibody than those of the Dox-untreated mice [Dox(-)] (Fig. 2D). The weak staining of the latter sample was probably due to the expression of endogenous RXR β , because the pancreas samples from non-Tg mice were similarly stained. These findings indicated that islet-spe-

cific expression of RXR β Δ C2 was inducible by Dox in the dnRXR Tg mice.

Suppression of RXRs increases the GSIS in vivo. To investigate the effect of dnRXR expression in β -cells on glucose homeostasis, OGTTs were performed after 2 weeks of Dox treatment (Dox On) and 2 weeks after the withdrawal of Dox treatment (Dox Off) (Fig. 3A). Interestingly, the dnRXR Tg mice showed significantly improved glucose tolerance under the expression of the dnRXR β (Dox On) compared with after the withdrawal of the Dox treatment (Dox Off) (Fig. 3B). Plasma insulin levels at 10 min after glucose administration were significantly higher under the Dox treatment (Dox On) compared with after the withdrawal of the Dox treatment (Dox Off) (Fig. 3C). The non-Tg control mice showed no significant change in the glucose tolerance with Dox treatment (data not shown). In a separate experiment, we examined whether the Dox treatment affected the body weight of the dnRXR Tg mice. Eight-week-old dnRXR Tg mice were maintained with or without Dox treatment ($n = 5$ each) for 2 weeks, and their body weights were measured. The result showed that there were no significant changes in the body weight between Dox-treated and Dox-untreated mice. Therefore, the improved glucose tolerance seen under the expression of the dnRXR β was mostly due to the improved response of β -cells to glucose.

We then examined the GSIS of isolated islets. In this analysis, the effect of 9cRA, an RXR agonist, was also examined. At 9 and 27 mmol/l glucose, the insulin secretion of the Dox(+) islets was significantly higher (~ 1.3 -fold) than that of the Dox(-) islets (Fig. 4A). Interestingly, 9cRA treatment significantly reduced the insulin secretion at the high glucose concentration both from the Dox(+) and Dox(-) islets. This effect of 9cRA was not observed at 3 or 9 mmol/l glucose.

To examine whether expression of the dnRXR β affected the transcription of insulin genes, the mRNA for the two insulin genes was quantified. The total RNA of islets isolated from Dox-treated and Dox-untreated mice was subjected to semi-quantitative RT-PCR analyses for the insulin 1 and insulin 2 genes. The results showed no significant differences in the expression level of these genes between the Dox(+) and Dox(-) islets (data not shown). We further examined whether expression of dnRXR β affected the insulin content of the pancreas. Pancreases were isolated from Dox-treated and Dox-untreated mice, and insulin content was measured. No significant differences were observed in the insulin content between the Dox(+) and Dox(-) pancreases (Fig. 4B). These results suggested that the expression of the dnRXR β affected insulin secretion through a mechanism occurring after insulin production.

dnRXR β increases the GSIS in a β -cell line. To examine the molecular mechanism underlying the elevated GSIS of islets cells by the expression of the dnRXR β , we sought to establish β -cell lines with Tet-inducible RXR β Δ C2 expression using a triple-Tg mouse strategy involving the IT-6 Tg mouse expressing the SV40 T antigen gene under the human insulin promoter (16). A total of 22 β -cell lines were established from each insulinoma developed in the pancreases of the triple-Tg mice and were tested for GSIS. Most lines exhibited appropriate GSIS. Two lines (19 and 21) were ultimately selected, termed dnRXR-MIN6 cells, and subjected to further analyses. Both clones showed similar results, and the data with clone 19 were presented. In dnRXR-MIN6 cells, the stable expres-




FIG. 2. Islet-specific induction of RXR $\beta\Delta C2$ in the Ins-rtTA/TetO-RXR $\beta\Delta C2$ double-Tg mice. The total RNA of the pancreas and other organs was subjected to RT-PCR analyses. The rtTA transgene expression was detected only in the pancreas samples from three different Tg mice and not in the other organs or in the non-Tg pancreas (A, upper panel). Hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used as an internal control (A, lower panel). Immunohistochemistry for rtTA in the pancreas of the Ins-rtTA Tg mouse (B, right panel) or a non-Tg mouse (B, left panel) is shown. The islets in the pancreas (arrowhead) of the Tg mouse were stained by an anti-rtTA antibody. The scale bars represent 100 μ m. By RT-PCR, expression of the RXR $\beta\Delta C2$ transgene was detected in the islets from two different double-Tg mice treated with Dox, but not in those from two untreated mice (C). D: Immunohistochemistry of the pancreas of an Ins-rtTA/TetO-RXR $\beta\Delta C2$ double-Tg mouse using an anti-RXR β antibody. Magnified views of the islets before (left panel) and after (right panel) Dox treatment are shown. Lower panels show double staining of the same islets with anti-RXR β (green) and anti-insulin (red) antibodies. Dox treatment induced a high-level expression of the dnRXR β in the islet β -cells of the double-Tg mouse. Scale bars represent 100 μ m. (A high-quality digital representation of this figure is available in the online issue.)

sion of rtTA and the Dox-mediated induction of RXR $\beta\Delta C2$ were confirmed by RT-PCR analysis, Western blotting, and immunocytochemistry (Fig. 5A–C). We also confirmed that Dox treatment affected neither the proliferation nor apoptosis of dnRXR-MIN6 cells (supplementary Figs. 1 and 2).

After incubation with or without Dox for 4 days, insulin secretion was measured at different glucose

concentrations. In this analysis, the effect of 9cRA was also examined. At 10 and 25 mmol/l glucose, the insulin secretion of the Dox-treated cells was significantly higher (1.5-fold) than that of the Dox-untreated cells (Fig. 5D). Interestingly, 9cRA treatment significantly reduced the insulin secretion at the high glucose concentration from both Dox-treated and untreated dnRXR-




FIG. 3. Experimental protocols for the Dox treatment (A) and OGTT in the dnRXR Tg mice (B and C). The Dox-containing water was given for 2 weeks and renewed every 4 days. The OGTTs were performed after 2 weeks of the Dox treatment (Dox On) and 2 weeks after the withdrawal of the Dox treatment (Dox Off). Compared with the Dox On state, the withdrawal of Dox (Dox Off) deteriorated the glucose tolerance. Plasma insulin levels were also measured at each time point (C). Values are expressed as the mean \pm SE. Statistical analyses were carried out by the Student *t* test. **P* < 0.05, ***P* < 0.01. *n* = 6.

MIN6 cells. This effect of 9cRA was not observed at 3 or 10 mmol/l glucose.

cDNA microarray analysis. RXRs function as transcription factors in a homodimeric or heterodimeric form. Therefore, the induced expression of the dnRXR β must influence the transcriptional levels of various target genes, some of which are assumed to be related to the regulation of insulin secretion in β -cells. We used high-density (Affymetrix) oligonucleotide microarrays to identify genes that were differentially expressed by the Dox-treated and untreated dnRXR-MIN6 cells. To correct for dye bias and exclude false-positive genes, dye swapping and subsequent normalization were performed. Supplementary Tables 2 and 3 list the genes for which a mean twofold or greater change in transcript level was demonstrated in the dye-swap experiment. We noted that the list included genes that might be related to the regulation of insulin secretion. We selected some of these genes to analyze by real-time PCR (Fig. 6). The results showed that these genes were clearly down- or upregulated by the Dox treatment, consistent with the microarray analysis.

DISCUSSION

Several studies have shown that RXR agonists have a beneficial effect on glucose tolerance in type 2 diabetes.




FIG. 4. Analysis of insulin secretion in the dnRXR Tg mice. Islets were isolated from Dox-treated and -untreated dnRXR Tg mice in the presence and absence of Dox, respectively (A). Insulin secretion from isolated islets in response to different concentrations of glucose is shown (*n* = 5–6 each). The effect of 9cRA treatment on the GSIS was also examined (A). For measurement of insulin content, dnRXR Tg mice with or without 2 weeks of Dox treatment were killed, and their pancreases were isolated (*n* = 6 each) (B). Values are expressed as the mean \pm SE. Statistical analyses were carried out by the Student *t* test. **P* < 0.05, ***P* < 0.01.

The RXR agonist LG100268 was reported to protect the insulin secretory capacity in the *db/db* mouse, a model for this disease (19,20). A recent report also showed that LG101506, a heterodimer-selective RXR stimulator, also has insulin-sensitizing activity in the *fal/fal* rat (21). Although these data suggest that RXR agonists are beneficial for glucose tolerance, there has been no direct evidence for an effect of RXR on the insulin secretory mechanism in β -cells. Thus, to elucidate the function of RXRs in β -cells, we produced a Tg mouse and established β -cell lines in which conditionally inducible dnRXR gene expression was achieved.

The dnRXR Tg mice under the Dox treatment showed improved glucose tolerance compared with the same mice after the removal of Dox (Fig. 3B). Consistently, plasma insulin levels after glucose administration were significantly higher under the Dox treatment compared with after the removal of Dox (Fig. 3C). The insulin secretion at high glucose concentration was significantly increased in the isolated islets of dnRXR Tg mice by Dox treatment, suggesting that the suppression of RXR function led to the increased insulin secretory response by glucose stimulation (Fig. 4A). Moreover, we confirmed that the expression of a dnRXR enhanced the GSIS in a transgenic β -cell line, dnRXR-MIN6. Our findings suggest that RXR acts as a negative regulator of the high-glucose response in β -cells, which was further supported by the negative effect of 9cRA on the GSIS at high glucose in isolated islets and also in dnRXR-MIN6 cells (Figs. 4A and 5D). Such negative effect of 9cRA was seen, even under the dnRXR β overex-




FIG. 5. Establishment of dnRXR-MIN6 cells and their GSIS. RT-PCR (A), Western blotting (B), and immunocytochemical analyses (C) were performed to detect the expression of rtTA and RXR $\beta\Delta C2$ in this cell line. Dox treatment of the dnRXR-MIN6 cells induced the expression of the RXR $\beta\Delta C2$ mRNA (A) and protein (B). Immunocytochemical analyses also showed the induction of the dnRXR β by Dox treatment in the nuclei of these cells (C). The scale bars represent 100 μ m. dnRXR-MIN6 cells were cultured with or without Dox for 4 days. 9cRA was added to the medium for the last 2 days of culture. Insulin secretion was measured at different glucose concentrations ($n = 4$ each) (D). Values are expressed as the mean \pm SE. Statistical analyses were carried out by the Student t test. * $P < 0.05$, ** $P < 0.01$. (A high-quality digital representation of this figure is available in the online issue.)

pression for both isolated islets and dnRXR-MIN6 cells (Figs. 4A and 5D). It was probably due to incomplete inhibition of the RXR function by the dominant-negative form of RXR β .

In contrast, the basal insulin secretion at 3 mmol/l glucose from isolated islets or dnRXR-MIN6 cells was not significantly affected by the suppression of RXR (Fig. 4B). In addition, the suppression of insulin secretion by 9cRA treatment was seen only at high glucose for both isolated islets and dnRXR-MIN6 cells (Figs. 4A and 5D). These findings suggested that RXR might function to inhibit excessive insulin release under high-glucose conditions. These opposing results for insulin release between the high- and low-glucose responses suggest that the function

of the RXR on β -cells may change, depending on the ambient glucose concentration. Thus, RXR may deeply participate in the regulatory mechanisms of GSIS.

Although the mechanism of the inhibitory effect of RXR is unknown, several reports suggest that RXR elicits diverse effects in β -cells by combining with different dimerization partners. PPAR- γ agonists are reported to prevent the impairment of the insulin secretory capacity induced by oxidative stress and lipotoxicity (22). A recent report showed that the combination of a PPAR- α agonist and an RXR agonist acted synergistically and led to protection against lipotoxicity in β -cells (23). Thus, the activation of PPAR/RXR signaling protects β -cells against oxidative stress and apoptosis. LXR is another het-




FIG. 6. Real-time PCR analysis of several candidate genes. Microarray analysis revealed a number of genes that were downregulated or upregulated by Dox. Some of these genes (downregulated: *Hes5*, *Mki67*, *Nr2f6*, *Hk1*, and *Nkx6-2*; upregulated: *Itpa*) were subjected to real-time PCR analysis. The relative expression levels (mean \pm SE) are shown. Statistical analyses were carried out by Student *t* test. **P* < 0.05, ***P* < 0.01.

erodimeric partner of RXR (24,25). Recent reports showed that, in contrast to PPAR/RXR, the activation of LXR/RXR signaling inhibits cell proliferation and induces apoptosis in β -cells (26,27). Efanov et al. (28) showed that the LXR agonist T0901317 enhances the glucose-induced insulin release from MIN6 cells, but the addition of 9cRA inhibits the effect of T0901317, especially on the insulin release response to high glucose. Thus, the function of RXR may be altered by its heterodimeric partner in β -cells.

RXR forms heterodimers with various partners of the nuclear hormone receptor family. To identify genes regulated by RXRs, we performed an oligonucleotide microarray analysis of dnRXR-MIN6 cells before and after induction of the dnRXR β . The results revealed a number of genes that were upregulated or downregulated by the Dox treatment (supplementary Tables 2 and 3, respectively; Fig. 6). The downregulated genes included *Strab6*, *Hk1*, *Kcnk9*, *Nr2f6*, *Hes5*, *cMaf*, and *Mki67*. *Strab6* was first identified as a retinoic acid-stimulated gene, and it encodes a membrane receptor for retinol-binding protein that mediates the cellular uptake of vitamin A (29). The finding that this retinoic acid-stimulated gene was downregulated by dnRXR expression indicates that our dnRXR Tg mouse system worked as expected.

Hk1 encodes hexokinase, which has a lower K_m for glucose than glucokinase, the major isozyme in β -cells. The expression levels of *Hk1* might affect the insulin secretion from dnRXR-MIN6 cells (30). *Kcnk9* (*Task3*)

encodes an acid-sensitive member of the two-pore-domain background K^+ (K_{2P}) channel family (31). K_{2P} channels contribute to the resting membrane potential by allowing K^+ to leak out of the cell. Thus, the downregulation of *Kcnk9* might influence the insulin secretion.

cMaf is one of the *large-Maf* transcription factor family genes, which also includes *MafA* and *MafB*. These factors are reported to be expressed in β -cells and to function as transcription factors for the insulin gene (32). *Nr2f6* (*Ear2*) encodes an orphan nuclear receptor, which is an RXR binding partner (33). However, the role of NR2F6 in β -cells has not been reported. *Hes5* is an effector protein in Notch signaling and belongs to the *Hes* family, as does *Hes1*, whose role in β -cells has been studied. The inhibition of *Hes1* expression using small hairpin RNA reduces the proliferation and dedifferentiation of β -cells (34,35). Another downregulated gene, *Nkx6-2*, encodes a transcription factor that is required for endocrine development in the pancreas (36).

Among the genes upregulated by the expression of the dnRXR were those involved in transcription (*Gtf2a2*, *Gtf2h3*, *Trfp*, *Lsm1*, *Lsm8*, *Polr3k*, and *Cdca4*), protein synthesis (*Rpl22*, *Rps27l*, *Rpl13Rps18*, *Rps25*, *Rpl15*, *Nat5*, and *Senp3*), signal transduction (*Itpa*), protein trafficking (*Sec61b*, *Vps22*, *Lztr1*, *Arfgap3*, *Rab37*, *Fkbp4*, and *Trappc3*), and mitochondrial function (*Ndufa4*, *Atp5j2*, *Cyb561d1*, *Mrpl44*, *Mrps5*, *Slc25a11*, and *Cyb5*). These genes could contribute to the elevation of the secretory capacity of β -cells.

The Tet-On system, which provides a tissue-specific and inducible expression of transgenes in animals, is suitable for investigating the functions of genes that have not been well characterized *in vivo*. Here, we successfully applied the Tet-On system to express a dnRXR specifically in β -cells. Our data suggest that RXRs inhibit insulin secretion from β -cells at high glucose levels. In addition, our DNA microarray analysis suggested several candidate genes that might be involved in this regulation. Although further studies on partners of RXRs and their target genes are needed, our finding that RXRs have multiple functions in the insulin secretion from β -cells may lead to novel therapeutic strategies for treating the impaired insulin secretion in type 2 diabetes.

ACKNOWLEDGMENTS

No potential conflicts of interest relevant to this article were reported.

S.M. researched data and wrote the manuscript. H.T., Y.M., F.T., and T.Y. researched data. E.Y. and H.I. contributed to the discussion. K.O. researched data and reviewed/edited the manuscript. J.-i.M. researched data and wrote the manuscript.

The authors are grateful to Mayu Yamamoto and Masafumi Ashida of Osaka University for technical assistance. We acknowledge the editorial assistance of Leslie A. Miglietta and Grace E. Gray, Clarity Editing. This work was supported by a Grant-in-Aid from the Ministry of Education, Science, Sports, and Culture of Japan.

REFERENCES

- Shulman AI, Mangelsdorf DJ. Retinoid X receptor heterodimers in the metabolic syndrome. *N Engl J Med* 2005;353:604–615
- Szanto A, Narkar V, Shen Q, Uray IP, Davies PJ, Nagy L. Retinoid X receptors: X-ploring their (patho)physiological functions. *Cell Death Diff* 2004;11(Suppl. 2):S126–S143
- Ziouzenkova O, Plutzky J. Retinoid metabolism and nuclear receptor

- responses: new insights into coordinated regulation of the PPAR-RXR complex. *FEBS Lett* 2003;582:32–38
4. Fernandez-Mejia C, Davidson MB. Regulation of glucokinase and proinsulin gene expression and insulin secretion in RIN-m5F cells by dexamethasone, retinoic acid, and thyroid hormone. *Endocrinology* 1992;130:1660–1668
 5. Chertow BS, Driscoll HK, Goking NQ, Primerano D, Cordle MB, Matthews KA. Retinoid-X receptors and the effects of 9-cis-retinoic acid on insulin secretion from RINm5F cells. *Metabolism* 1997;46:656–660
 6. Cabrera-Valladares G, German MS, Matschinsky FM, Wang J, Fernandez-Mejia C. Effect of retinoic acid on glucokinase activity and gene expression and on insulin secretion in primary cultures of pancreatic islets. *Endocrinology* 1999;140:3091–3096
 7. Blumentrath J, Neye H, Verspohl EJ. Effects of retinoids and thiazolidinediones on proliferation, insulin release, insulin mRNA, GLUT 2 transporter protein and mRNA of INS-1 cells. *Cell Biochem Funct* 2001; 19:159–169
 8. Ravnskjaer K, Boergesen M, Rubi B, Larsen JK, Nielsen T, Fridriksson J, Maechler P, Mandrup S. Peroxisome proliferator-activated receptor α (PPAR α) potentiates, whereas PPAR γ attenuates, glucose-stimulated insulin secretion in pancreatic β -cells. *Endocrinology* 2005;146:3266–3276
 9. Kastner P, Mark M, Leid M, Gansmuller A, Chin W, Grondona JM, Décimo D, Krezel W, Dierich A, Chambon P. Abnormal spermatogenesis in RXR β mutant mice. *Genes Dev* 1996;10:80–92
 10. Sucov HM, Dyson E, Gumeringer CL, Price J, Chien KR, Evans RM. RXR α mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. *Genes Dev* 1996;8:1007–1018
 11. Blanco JC, Dey A, Leid M, Minucci S, Park BK, Jurutka PW, Haussler MR, Ozato K. Inhibition of ligand induced promoter occupancy in vivo by a dominant negative RXR. *Genes Cells* 1996;1:209–221
 12. Gossen M, Freundlieb S, Bender G, Müller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. *Science* 1995;268:1766–1769
 13. Ray P, Tang W, Wang P, Homer R, Kuhn C 3rd, Flavell RA, Elias JA. Regulated overexpression of interleukin 11 in the lung: use to dissociate development-dependent and -independent phenotypes *J Clin Invest* 1997; 100:2501–2511
 14. Lottmann H, Vanselow J, Hessabi B, Walther R. The Tet-On system in transgenic mice: inhibition of the mouse *pdx-1* gene activity by antisense RNA expression in pancreatic β -cells. *J Mol Med* 2001;79:321–328
 15. Yamato E, Ikegami H, Tahara Y, Fukuda M, Cha T, Kawaguchi Y, Fujioka Y, Noma Y, Shima K, Ogihara T. Glyburide enhances insulin gene expression and glucose-induced insulin release in isolated rat islets. *Biochem Biophys Res Commun* 1994;199:327–333
 16. Miyazaki J, Araki K, Yamato E, Ikegami H, Asano T, Shibasaki Y, Oka Y, Yamamura K. Establishment of a pancreatic β cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. *Endocrinology* 1990;127:126–132
 17. Taniguchi H, Yamato E, Tashiro F, Ikegami H, Ogihara T, Miyazaki J. Beta-cell neogenesis induced by adenovirus-mediated gene delivery of transcription factor *pdx-1* into mouse pancreas. *Gene Ther* 2003;10:15–23
 18. Miyazaki J, Takaki S, Araki K, Tashiro F, Tominaga A, Takatsu K, Yamamura K. Expression vector system based on the chicken β -actin promoter directs efficient production of interleukin-5. *Gene* 1989;79:269–277
 19. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Paterniti JR Jr, Heyman RA. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. *Nature* 1997;386:407–410
 20. Lenhard JM, Lancaster ME, Paulik MA, Weiel JE, Binz JG, Sundseth SS, Gaskill BA, Lightfoot RM, Brown HR. The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic β -cell dysfunction. *Diabetologia* 1999;42:545–554
 21. Leibowitz MD, Ardecky RJ, Boehm MF, Broderick CL, Carfagna MA, Crombie DL, D'Arrigo J, Etgen GJ, Faul MM, Grese TA, Havel H, Hein NI, Heyman RA, Jolley D, Klausing K, Liu S, Mais DE, Mapes CM, Marschke KB, Michellys PY, Montrose-Rafizadeh C, Ogilvie KM, Pascual B, Rungta D, Tyhonas JS, Urcan MS, Wardlow M, Yumibe N, Reifel-Miller A. Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes. *Endocrinology* 2006;147:1044–1053
 22. Kim HI, Ahn YH. Role of peroxisome proliferator-activated receptor- γ in the glucose-sensing apparatus of liver and β -cells. *Diabetes* 2004;53(Suppl. 1):S60–S65
 23. Hellemans K, Kerckhofs K, Hannaert JC, Martens G, Van Veldhoven P, Pipeleers D. Peroxisome proliferator-activated receptor α -retinoid X receptor agonists induce β -cell protection against palmitate toxicity. *FEBS J* 2007;274:6094–6105
 24. Zhao C, Dahlman-Wright K. Liver X receptor in cholesterol metabolism. *J Endocrinol* 2010;204:233–240
 25. Sugden MC, Holness MJ. Role of nuclear receptors in the modulation of insulin secretion in lipid-induced insulin resistance. *Biochem Soc Trans* 2008;36:891–900
 26. Choe SS, Choi AH, Lee JW, Kim KH, Chung JJ, Park J, Lee KM, Park KG, Lee IK, Kim JB. Chronic activation of liver X receptor induces β -cell apoptosis through hyperactivation of lipogenesis: liver X receptor-mediated lipotoxicity in pancreatic β -cells. *Diabetes* 2007;56:1534–1543
 27. Wente W, Brenner MB, Zitzer H, Gromada J, Efanov AM. Activation of liver X receptors and retinoid X receptors induces growth arrest and apoptosis in insulin-secreting cells. *Endocrinology* 2007;148:1843–1849
 28. Efanov AM, Sewing S, Bokvist K, Gromada J. Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic β -cells. *Diabetes* 2004;53(Suppl. 3):S75–S78
 29. Kawaguchi R, Yu J, Honda J, Hu J, Whitelegge J, Ping P, Wiita P, Bok D, Sun H. A membrane receptor for retinoid binding protein mediates cellular uptake of vitamin A. *Science* 2007;315:820–825
 30. Ishihara H, Asano T, Tsukuda K, Katagiri H, Inukai K, Anai M, Kikuchi M, Yazaki Y, Miyazaki J, Oka Y. Overexpression of hexokinase I but not GLUT1 glucose transporter alters concentration dependence of glucose-stimulated insulin secretion in pancreatic beta-cell line MIN6. *J Biol Chem* 1994;269:3081–3087
 31. Goldstein SA, Bockenhauer D, O'Kelly I, Zilberberg N. Potassium leak channels and the KCNK family of two-P-domain subunits. *Nat Rev Neurosci* 2001;2:175–184
 32. Matsuoka TA, Zhao L, Artner I, Jarrett HW, Friedman D, Means A, Stein R. Members of the large Maf transcription family regulate insulin gene transcription in islet β cells. *Mol Cell Biol* 2003;23:6049–6062
 33. Warnecke M, Oster H, Revelli JP, Alvarez-Bolado G, Eichele G. Abnormal development of the locus coeruleus in *Ear2(Nr2f6)*-deficient mice impairs the functionality of the forebrain clock and affects nociception. *Genes Dev* 2005;19:614–625
 34. Bar Y, Russ HA, Knoller S, Ouziel-Yahalom L, Efrat S. HES-1 is involved in adaptation of adult human beta-cells to proliferation in vitro. *Diabetes* 2008;57:2413–2420
 35. Fujikura J, Hosoda K, Iwakura H, Tomita T, Noguchi M, Masuzaki H, Tanigaki K, Yabe D, Honjo T, Nakao K. Notch/Rbp-j signaling prevents premature endocrine and ductal cell differentiation in the pancreas. *Cell Metab* 2006;3:59–65
 36. Henseleit KD, Nelson SB, Kuhlbrodt K, Hennings JC, Ericson J, Sander M. NKX6 transcription factor activity is required for alpha- and beta-cell development in the pancreas. *Development* 2005;132:3139–3149